<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468674</url>
  </required_header>
  <id_info>
    <org_study_id>CBYM338E2202E1</org_study_id>
    <secondary_id>2015-000471-27</secondary_id>
    <nct_id>NCT02468674</nct_id>
  </id_info>
  <brief_title>A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study</brief_title>
  <official_title>A 24 Week Off Drug Extension, Parallel Group, Study Assessing Durability of Effect on Skeletal Muscle Strength and Function Following a 6-month Double-blind, Placebo Controlled Study Evaluating Bimagrumab in Older Adults With Sarcopenia (InvestiGAIT Extension)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study
      and the main objective was to determine the long-term durability of bimagrumab (BYM338)
      effect after a 6-month treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two populations were defined as below:

        -  Population I: Patients enrolled prior to the protocol amendment 1, who received
           bimagrumab 70 mg, 210 mg or 700 mg in the core study, were randomly assigned to two
           subgroups within each of three treatment arms to either receive bimagrumab at the same
           dose level or placebo. Patients receiving placebo in the core study continued receiving
           placebo in the extension study.

        -  Population II: Patients enrolled after protocol amendment 1, who received bimagrumab 700
           mg or placebo in the core study, did not receive study medication in the extension study
           and were followed-up per schedule defined in this protocol amendment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2015</start_date>
  <completion_date type="Actual">December 3, 2018</completion_date>
  <primary_completion_date type="Actual">December 3, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49</measure>
    <time_frame>Week 49</time_frame>
    <description>SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Population II: Short Physical Performance Battery (SPPB) Total Score at Week 49</measure>
    <time_frame>Week 49</time_frame>
    <description>SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Population I: 6-minute Walking Distance (6MWT) at Week 49</measure>
    <time_frame>Week 49</time_frame>
    <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population II: 6-minute Walking Distance (6MWT) at Week 49</measure>
    <time_frame>Week 49</time_frame>
    <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population I: Gait Speed at Week 49</measure>
    <time_frame>Week 49</time_frame>
    <description>Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population II: Gait Speed at Week 49</measure>
    <time_frame>Week 49</time_frame>
    <description>Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population I: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</measure>
    <time_frame>Week 49</time_frame>
    <description>ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population II: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</measure>
    <time_frame>Week 49</time_frame>
    <description>ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population I: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</measure>
    <time_frame>Week 49</time_frame>
    <description>LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population II: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</measure>
    <time_frame>Week 49</time_frame>
    <description>LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Follow-up (arm 1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo - one approximately every four weeks - over a 20-week period providing drug exposure for a total of 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Follow-up (arm 2)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimagrumab</intervention_name>
    <description>bimagrumab low dose bimagrumab moderate dose bimagrumab high dose
Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.</description>
    <arm_group_label>Follow-up (arm 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo
Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.</description>
    <arm_group_label>Follow-up (arm 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criterion:

        - Men and postmenopausal women aged 70 years or older that have participated in, and have
        completed the full study treatment period per protocol (24 weeks/EOT visit) in the
        preceding core study (CBYM338E2202)

        Exclusion criterion:

        - Any condition which should have led to treatment discontinuation per protocol in the core
        study (CBYM338E2202)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <zip>12000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Obu-city</city>
        <state>Aichi</state>
        <zip>474-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toyohashi-city</city>
        <state>Aichi</state>
        <zip>440-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mizunami-city</city>
        <state>Gifu</state>
        <zip>509 6134</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nara-city</city>
        <state>Nara</state>
        <zip>630-8581</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitaadachigun Inamachi</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitamoto-city</city>
        <state>Saitama</state>
        <zip>364-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi ku</city>
        <state>Tokyo</state>
        <zip>173 0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiyose-city</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>136-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suwon si</city>
        <state>Gyeonggi Do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>101990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albacete</city>
        <state>Castilla La Mancha</state>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genève 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2015</study_first_posted>
  <results_first_submitted>October 24, 2019</results_first_submitted>
  <results_first_submitted_qc>December 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 9, 2019</results_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcopenia, muscle wasting, elderly, strength, physical function, lean body mass, gait speed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02468674/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02468674/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in 30 centers in 12 countries: Australia (1), Belgium (1), Czech Republic (1), Denmark (1), France (2), Japan (10), Russia (4), South Korea (1), Spain (2), Switzerland (1), Taiwan (1), United States (5).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Population I: BYM338 700 mg</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Population I BYM338: 700 mg to Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Population I: BYM338 210 mg</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Population I BYM338: 210 mg to Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Population I: BYM338 70 mg</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Population I: BYM338 70 mg to Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Population I: Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Population: II BYM338 700 mg</title>
          <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
        </group>
        <group group_id="P9">
          <title>Population: II Placebo</title>
          <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="69"/>
                <participants group_id="P9" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="14"/>
                <participants group_id="P8" count="65"/>
                <participants group_id="P9" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient/Guardian Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
      <group_list>
        <group group_id="B1">
          <title>Population I: BYM338 700 mg</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Population I BYM338: 700 mg to Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Population I: BYM338 210 mg</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Population I BYM338: 210 mg to Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Population I: BYM338 70 mg</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Population I: BYM338 70 mg to Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Population I: Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Population: II BYM338 700 mg</title>
          <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
        </group>
        <group group_id="B9">
          <title>Population: II Placebo</title>
          <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="15"/>
            <count group_id="B8" value="69"/>
            <count group_id="B9" value="43"/>
            <count group_id="B10" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age Continuous for Population I</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="15"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.0" spread="4.90"/>
                    <measurement group_id="B2" value="79.4" spread="7.27"/>
                    <measurement group_id="B3" value="79.0" spread="1.58"/>
                    <measurement group_id="B4" value="74.8" spread="2.63"/>
                    <measurement group_id="B5" value="77.6" spread="6.75"/>
                    <measurement group_id="B6" value="81.6" spread="4.58"/>
                    <measurement group_id="B7" value="79.9" spread="4.22"/>
                    <measurement group_id="B10" value="79.2" spread="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age Continuous for Population II</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="43"/>
                    <count group_id="B10" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B8" value="79.8" spread="5.05"/>
                    <measurement group_id="B9" value="78.2" spread="5.29"/>
                    <measurement group_id="B10" value="79.2" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Gender for Population I</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="15"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Gender for Population II</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="43"/>
                    <count group_id="B10" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="40"/>
                    <measurement group_id="B9" value="29"/>
                    <measurement group_id="B10" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race/Ethnicity for Population I</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="15"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B10" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="15"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="15"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B10" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race/Ethnicity for Population II</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="43"/>
                    <count group_id="B10" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="43"/>
                    <count group_id="B10" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B8" value="56"/>
                    <measurement group_id="B9" value="40"/>
                    <measurement group_id="B10" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="43"/>
                    <count group_id="B10" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="43"/>
                    <count group_id="B10" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Population I: Short Physical Performance Battery (SPPB) total score at Week 25</title>
          <description>Baseline Extension Visit = Week 25. SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="15"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" spread="2.17"/>
                    <measurement group_id="B2" value="10.4" spread="1.34"/>
                    <measurement group_id="B3" value="8.6" spread="1.67"/>
                    <measurement group_id="B4" value="8.5" spread="1.91"/>
                    <measurement group_id="B5" value="8.9" spread="2.04"/>
                    <measurement group_id="B6" value="8.0" spread="3.27"/>
                    <measurement group_id="B7" value="9.1" spread="1.58"/>
                    <measurement group_id="B10" value="8.9" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Population II: Short Physical Performance Battery (SPPB) total score at Week 25</title>
          <description>Baseline Extension Visit = Week 25. SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="43"/>
                    <count group_id="B10" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B8" value="8.5" spread="2.17"/>
                    <measurement group_id="B9" value="8.2" spread="2.25"/>
                    <measurement group_id="B10" value="8.4" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Population I: 6-minute walking distance (6MWT) at Week 25</title>
          <description>Baseline Extension Visit = Week 25. The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway.</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="15"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="302.73" spread="130.22"/>
                    <measurement group_id="B2" value="353.10" spread="66.17"/>
                    <measurement group_id="B3" value="313.67" spread="71.39"/>
                    <measurement group_id="B4" value="361.07" spread="80.11"/>
                    <measurement group_id="B5" value="305.24" spread="111.34"/>
                    <measurement group_id="B6" value="286.94" spread="119.37"/>
                    <measurement group_id="B7" value="352.18" spread="123.55"/>
                    <measurement group_id="B10" value="327.49" spread="106.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Population II: 6-minute walking distance (6MWT) at Week 25</title>
          <description>Baseline Extension Visit = Week 25. The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway.</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="43"/>
                    <count group_id="B10" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B8" value="307.84" spread="99.96"/>
                    <measurement group_id="B9" value="315.61" spread="95.74"/>
                    <measurement group_id="B10" value="310.81" spread="98.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Population I: Gait speed at Week 25</title>
          <description>Baseline Extension Visit = Week 25. Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="15"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" spread="0.20"/>
                    <measurement group_id="B2" value="0.9" spread="0.13"/>
                    <measurement group_id="B3" value="0.9" spread="0.27"/>
                    <measurement group_id="B4" value="0.9" spread="0.12"/>
                    <measurement group_id="B5" value="0.8" spread="0.19"/>
                    <measurement group_id="B6" value="0.6" spread="0.28"/>
                    <measurement group_id="B7" value="0.8" spread="0.19"/>
                    <measurement group_id="B10" value="0.8" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Population II: Gait speed at Week 25</title>
          <description>Baseline Extension Visit = Week 25. Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.</description>
          <population>160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="69"/>
                    <count group_id="B9" value="43"/>
                    <count group_id="B10" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B8" value="0.8" spread="0.23"/>
                    <measurement group_id="B9" value="0.8" spread="0.22"/>
                    <measurement group_id="B10" value="0.8" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49</title>
        <description>SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).</description>
        <time_frame>Week 49</time_frame>
        <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Population I: BYM338 700 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Population I BYM338: 700 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Population I: BYM338 210 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Population I BYM338: 210 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Population I: BYM338 70 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Population I: BYM338 70 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Population I: Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49</title>
          <description>SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).</description>
          <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="3.86"/>
                    <measurement group_id="O2" value="10.2" spread="1.92"/>
                    <measurement group_id="O3" value="8.0" spread="2.35"/>
                    <measurement group_id="O4" value="8.0" spread="2.65"/>
                    <measurement group_id="O5" value="9.5" spread="2.17"/>
                    <measurement group_id="O6" value="7.5" spread="3.78"/>
                    <measurement group_id="O7" value="9.6" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Population I: SPPB total score at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.759</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Population I: SPPB total score at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Population I: SPPB total score at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.144</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: SPPB total score at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.648</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: SPPB total score at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.929</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: SPPB total score at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.530</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Population II: Short Physical Performance Battery (SPPB) Total Score at Week 49</title>
        <description>SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).</description>
        <time_frame>Week 49</time_frame>
        <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Population: II BYM338 700 mg</title>
            <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Population: II Placebo</title>
            <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Population II: Short Physical Performance Battery (SPPB) Total Score at Week 49</title>
          <description>SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).</description>
          <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="2.40"/>
                    <measurement group_id="O2" value="8.8" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Population II: SPPB total score at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.839</p_value>
            <method>ANCOVA</method>
            <method_desc>Difference in the least square means (SE)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population I: 6-minute Walking Distance (6MWT) at Week 49</title>
        <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.</description>
        <time_frame>Week 49</time_frame>
        <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Population I: BYM338 700 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Population I BYM338: 700 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Population I: BYM338 210 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Population I BYM338: 210 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Population I: BYM338 70 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Population I: BYM338 70 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Population I: Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Population I: 6-minute Walking Distance (6MWT) at Week 49</title>
          <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.</description>
          <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318.2" spread="159.55"/>
                    <measurement group_id="O2" value="354.1" spread="69.98"/>
                    <measurement group_id="O3" value="304.1" spread="63.05"/>
                    <measurement group_id="O4" value="361.5" spread="144.53"/>
                    <measurement group_id="O5" value="316.1" spread="97.87"/>
                    <measurement group_id="O6" value="273.4" spread="154.03"/>
                    <measurement group_id="O7" value="368.7" spread="108.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Population I: 6MWT at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.669</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Population I: 6MWT at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.773</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Population I: 6MWT at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.290</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: 6MWT at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.766</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: 6MWT at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.885</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: 6MWT at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.840</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population II: 6-minute Walking Distance (6MWT) at Week 49</title>
        <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.</description>
        <time_frame>Week 49</time_frame>
        <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Population: II BYM338 700 mg</title>
            <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Population: II Placebo</title>
            <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Population II: 6-minute Walking Distance (6MWT) at Week 49</title>
          <description>The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.</description>
          <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321.2" spread="105.13"/>
                    <measurement group_id="O2" value="323.1" spread="96.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Population II: 6MWT at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.367</p_value>
            <method>ANCOVA</method>
            <method_desc>Difference in the least square means (SE)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population I: Gait Speed at Week 49</title>
        <description>Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.</description>
        <time_frame>Week 49</time_frame>
        <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Population I: BYM338 700 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Population I BYM338: 700 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Population I: BYM338 210 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Population I BYM338: 210 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Population I: BYM338 70 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Population I: BYM338 70 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Population I: Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Population I: Gait Speed at Week 49</title>
          <description>Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.</description>
          <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.35"/>
                    <measurement group_id="O2" value="1.0" spread="0.18"/>
                    <measurement group_id="O3" value="0.9" spread="0.17"/>
                    <measurement group_id="O4" value="1.1" spread="0.24"/>
                    <measurement group_id="O5" value="0.9" spread="0.15"/>
                    <measurement group_id="O6" value="0.7" spread="0.35"/>
                    <measurement group_id="O7" value="0.8" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Population I: Gait speed at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.875</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Population I: Gait speed at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.909</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Population I: Gait speed at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: Gait speed at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.632</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: Gait speed at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.310</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: Gait speed at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.321</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population II: Gait Speed at Week 49</title>
        <description>Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.</description>
        <time_frame>Week 49</time_frame>
        <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Population: II BYM338 700 mg</title>
            <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Population: II Placebo</title>
            <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Population II: Gait Speed at Week 49</title>
          <description>Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.</description>
          <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.24"/>
                    <measurement group_id="O2" value="0.9" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Population II: Gait speed at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.395</p_value>
            <method>ANCOVA</method>
            <method_desc>Difference in the least square means (SE)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population I: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</title>
        <description>ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.</description>
        <time_frame>Week 49</time_frame>
        <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Population I: BYM338 700 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Population I BYM338: 700 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Population I: BYM338 210 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Population I BYM338: 210 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Population I: BYM338 70 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Population I: BYM338 70 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Population I: Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Population I: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</title>
          <description>ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.</description>
          <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
          <units>kg/m^2</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="7.22"/>
                    <measurement group_id="O2" value="6.0" spread="14.05"/>
                    <measurement group_id="O3" value="6.1" spread="8.08"/>
                    <measurement group_id="O4" value="5.8" spread="15.08"/>
                    <measurement group_id="O5" value="5.9" spread="14.19"/>
                    <measurement group_id="O6" value="5.2" spread="14.85"/>
                    <measurement group_id="O7" value="5.6" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Population I: ASMI at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.120</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Population I: ASMI at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.297</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Population I: ASMI at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: ASMI at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: ASMI at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.106</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: ASMI at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.211</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population II: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</title>
        <description>ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.</description>
        <time_frame>Week 49</time_frame>
        <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Population: II BYM338 700 mg</title>
            <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Population: II Placebo</title>
            <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Population II: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</title>
          <description>ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.</description>
          <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
          <units>kg/m^2</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="14.36"/>
                    <measurement group_id="O2" value="5.5" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Population II: ASMI at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>ANCOVA</method>
            <method_desc>Difference in the least square geometric means</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population I: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</title>
        <description>LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect</description>
        <time_frame>Week 49</time_frame>
        <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Population I: BYM338 700 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Population I BYM338: 700 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Population I: BYM338 210 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Population I BYM338: 210 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Population I: BYM338 70 mg</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Population I: BYM338 70 mg to Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Population I: Placebo</title>
            <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Population I: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</title>
          <description>LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect</description>
          <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
          <units>kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" spread="21.11"/>
                    <measurement group_id="O2" value="34.0" spread="17.76"/>
                    <measurement group_id="O3" value="35.5" spread="15.39"/>
                    <measurement group_id="O4" value="32.6" spread="25.23"/>
                    <measurement group_id="O5" value="34.9" spread="21.16"/>
                    <measurement group_id="O6" value="34.0" spread="18.47"/>
                    <measurement group_id="O7" value="32.6" spread="17.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Population I: LBM at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Population I: LBM at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.283</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Population I: LBM at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.323</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: LBM at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: LBM at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.179</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Population I: LBM at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>One-sided test at the 0.025 significance level.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population II: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</title>
        <description>LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect</description>
        <time_frame>Week 49</time_frame>
        <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Population: II BYM338 700 mg</title>
            <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Population: II Placebo</title>
            <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Population II: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49</title>
          <description>LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect</description>
          <population>The Full Analysis Set (FAS), which consisted of all randomized patients to whom study treatment had been assigned, was considered. For post Week 25 assessments, only the subjects with assessment available at both the Visit and Week 25 are included in the calculation of the respective Visit statistics.</population>
          <units>kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" spread="25.01"/>
                    <measurement group_id="O2" value="33.7" spread="20.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Population II: LBM at Week 49</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>ANCOVA</method>
            <method_desc>Difference in the least square geometric means</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum treatment duration of 24 weeks</time_frame>
      <desc>Adverse events presented below are events considered to be treatment-emergent, therefore only events occurring in Population I are summarized. Patients in Population II did not receive study medication (were followed-up of-drug), thus any events occurring in this group were not treatment-emergent and are not captured in the summary.</desc>
      <group_list>
        <group group_id="E1">
          <title>Population I BYM338 700 mg</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Population I BYM338 700 mg to Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Population I BYM338 210 mg</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Population I BYM338 210 mg to Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Population I BYM338 70 mg</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Population I BYM338 70 mg to Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Population I Placebo</title>
          <description>Follow-up (arm 1): Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo – one approximately every four weeks – over a 20-week period providing drug exposure for a total of 24 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Population: II BYM338 700 mg</title>
          <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
        </group>
        <group group_id="E9">
          <title>Population: II Placebo</title>
          <description>Follow-up (arm 2): Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscle contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Body mass index decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device loosening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

